ADMA Biologics Inc vs The Coca-Cola Co K — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while The Coca-Cola Co K trades at $86.59 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 171.4× ADMA Biologics Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KO | |
|---|---|---|
Market Cap | $2.18B | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $89.08 |
52-Week Low | $7.60 | $65.67 |
Enterprise Value | $2.25B | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.
The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →